Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibody persistence after Menitorix or MenC conjugate vaccination in children up to 6 years of age
2008-007846-69Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2009
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of Hib-MenC-TT and Meningococcal group C polysaccharide conjugate vaccine in Haemophilus influenzae type b disease (Hib) and meningococcal disease (2 arms), sponsored by GSK. Primary endpoint: Persistence of immunogenicity with respect to components of the Hib-MenC conjugate vaccine at 3, 4 and 6 years of age. Started Mar 2009; status: completed.
02
Drugs
Hib-MenC-TTMeningococcal group C polysaccharide conjugate vaccine
03
Conditions
Haemophilus influenzae type b disease (Hib)meningococcal disease
Beyond the preview
Go deeper on 2008-007846-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007846-69.